ADA 2017

In this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about how doctors can educate patients on nutrition and diet issues, the advances in diabetes technology, and the complexities of diabetes multi-drug therapies.

Transcript coming soon.

In part 1 of this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about teaching medical students about the specifics of nutrition as it relates to diabetes management.

In part 2 of this Exclusive Interview, Dr. Mark Molitch shares his thoughts about technology, the latest meds, and what's coming down the pike in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about his ADA presentation on resulting diabetes diagnoses or hyperglycemia following islet pancreatic transplant surgery.

In part 4 of this Exclusive Interview, Dr. Mark Molitch shares his thoughts on the latest diabetes drug class, SGLT2, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 5 of this Exclusive Interview, Dr. Mark Molitch explains the changes in diabetes care that have resulted in the dramatic decrease in renal failure in diabetes patients in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 6 of this Exclusive Interview, Dr. Mark Molitch explains the diabetes treatment objective in patients who have undergone a transplant in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 7, the conclusion of this Exclusive Interview, Dr. Mark Molitch talks with with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the importance of good blood glucose control and continued control in post-transplant patients as referenced in his ADA presentation.

Dr. Todd Hobbs is Vice President and Chief Medical Officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system, and healthcare professionals. He provides overall medical guidance to Novo Nordisk’s diabetes and obesity-related projects. Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the medicine department for a large regional medical center in Kentucky. During this 10year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.